Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

DRUG3 trials

Sponsors

NRG Oncology, Fudan University, Fujian Cancer Hospital

Conditions

Adjuvant TherapyBreast CancerEarly Breast CancerHormone Receptor Positive / HER2-negative Breast CancerStage I Breast Cancer

Phase 2

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Not yet recruitingNCT07101159

Fujian Cancer HospitalAdjuvant Therapy, Early Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer

Start: 2025-09-30End: 2031-12-31Target: 200Updated: 2025-08-03

Phase 3

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

RecruitingNCT04852887

NRG OncologyStage I Breast Cancer

Start: 2021-06-23End: 2041-07-01Target: 1670Updated: 2026-04-23

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

RecruitingNCT07019363

Fudan UniversityAdjuvant Therapy, Breast Cancer

Start: 2025-06-15End: 2033-04-15Target: 1903Updated: 2026-01-21

Related Papers

Abstract PS5-08-20: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007

Clinical Cancer Research2026-02-17

Abstract P2-12-25: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007

Clinical Cancer Research2025-06-13

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology2025-05-28

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology2024-05-291 citations

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology2023-06-016 citations

Abstract OT1-12-01: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007

Cancer Research2023-03-012 citations

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology2022-06-0129 citations

Abstract P3-18-04: Evaluating <b>de</b>-escalation of <b>b</b>reast <b>r</b>adiation (<b>DEBRA</b>) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial

Cancer Research2022-02-151 citations